Novartis enters AI partnership with Oxford University

Novartis and the University of Oxford’s Big Data Institute (BDI) have joined forces to use artificial intelligence (AI) for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis tries to block generic versions of Gilenya, enforces new patent

30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Big Pharma

Novartis and Microsoft to collaborate on AI in medicine

3 October 2019 Novartis has teamed with Microsoft to launch a new artificial intelligence innovation lab, which it says has the potential to “transform” and “reimagine” medicine.

Big Pharma

Novartis and BenevolentAI sign AI oncology deal

9 September 2019 Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.